- Alkermes (NASDAQ:ALKS) completes acquisition of Rodin Therapeutics, a privately held biopharmaceutical company.
- More news on: Alkermes plc, Healthcare stocks news, Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc Company Name:
ALKS Stock Symbol:
Market:
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 PR Newswire DUBLIN , April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a pha...
Alkermes to Report First Quarter Financial Results on May 1, 2024 PR Newswire DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, Ma...
2024-04-10 09:00:04 ET Akash Tewari from Jefferies issued a price target of $50.00 for ALKS on 2024-04-10 07:44:00. The adjusted price target was set to $50.00. At the time of the announcement, ALKS was trading at $26.73. The overall price target consensus is at $31.33 w...